Contact information
Research groups
Lisa Stockdale
MPH, PhD
Senior Immunologist
Pre-erythrocytic Malaria Clinical Trials
Senior Immunologist
Pre-erythrocytic Malaria Clinical Trials
As the Senior immunologist in the pre-erythrocytic malaria vaccine group, I coordinate the clinical immunology of all R21/Matrix-M vaccine trials. These include trials studying vaccine immunogenicity in populations with co-morbidities, different age groups, and using alternative dosing regimens.
Having spent 5 years in Industry working in small molecule drug development, I completed a Master of International Public Health at York University, and a PhD in Tuberculosis Vaccine Immunology at London School of Hygiene and Tropical Medicine, before joining the Oxford Vaccine Group as a post-doc where I conducted research on Typhoid conjugate vaccine immunology and Covid-19 vaccine development and immunology.
I joined the Pre-erythrocytic Malaria group at the Jenner Institute in 2021. My research interests include correlates of vaccine-induced protection, investigation of mediators of antibody function, immunological interactions between different pathogens and sero-epidemiology.
I am an Early Career Researcher representative for the Medical Sciences Division and the Nuffield Department of Medicine and a lead of the Jenner Research Staff Network.
Recent publications
-
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9
-
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya
Sang S. et al, (2024)
-
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), The Lancet. Infectious diseases, 24, 465 - 475
-
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
-
Distinct glycosylation and functional profile of typhoid vaccine-induced antibodies in a UK challenge study and Nepalese children
Stockdale LK. et al, (2022), Frontiers in Analytical Science, 2